-
Fapon Biotech Partners with Sansure to Develop Next-Generation Diagnostic Solutions
•
China-based biotech Fapon Biotech Inc. has formed a strategic partnership with molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289). The collaboration aims to integrate Fapon’s leading artificial intelligence (AI) molecular enzyme development technology with Sansure’s extensive clinical diagnosis experience to create more accurate and reliable next-generation diagnostic solutions. Partnership DetailsThe…
-
Sansure Biotech Plans RMB130 Million Investment in Shenzhen GeneMind for Gene Sequencing Expansion
•
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) announced plans to invest RMB130 million (USD17.9 million) in compatriot firm Shenzhen GeneMind Biosciences Co., Ltd., a gene sequencer specialist. This investment aims to enhance Sansure’s industry chain layout in the gene sequencing sector and boost its comprehensive competitiveness. Transaction DetailsThe…
-
Sansure Biotech to Acquire Sinobioway Hygene for $110M to Boost Product Pipeline
•
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced plans to acquire 100% of the stakes in compatriot firm Zhongshan Sinobioway Hygene Biomedicine Co., Ltd., a genetic engineering biopharma. The transaction is valued at RMB 807.5 million (USD 110 million), marking a significant strategic move for Sansure. Acquisition…
-
Sansure Biotech’s HPV Detection Kit Receives NMPA Approval for Comprehensive Screening
•
Sansure Biotech Inc., a molecular diagnostics specialist based in China and listed on the Shanghai Stock Exchange (SHA: 688289), has announced that it has received marketing approval from the National Medical Products Administration for its human papillomavirus (HPV) nucleic acid detection kit. This kit, which uses the PCR fluorescent probe…
-
Sansure Biotech Wins NMPA Nod for ALDH2 Gene Polymorphism Detection Kit
•
Sansure Biotech Inc., (SHA: 688289), a leading molecular diagnostics company based in China, has announced that it has obtained marketing approval from the National Medical Products Administration (NMPA) for its nucleic acid detection kit for the human ALDH2 gene polymorphism, utilizing the PCR fluorescent probe method. The kit is designed…
-
China’s Sansure Biotech Launches Approved Kit for Alzheimer’s and Cardiovascular Risk Assessment
•
Sansure Biotech Inc. (SHA: 688289), a China-based leader in molecular diagnostics, has secured marketing approval from the National Medical Products Administration (NMPA) for its human ApoE gene polymorphism nucleic acid detection kit, utilizing the PCR fluorescent probe method. This kit is classified as a Category III medical device. The detection…
-
Sansure Biotech’s MTHFR Gene Detection Kit Receives NMPA Approval, Aids in Pregnancy Health Management
•
Sansure Biotech Inc. (SHA: 688289), a specialist in molecular diagnostics based in China, has achieved a regulatory milestone with the National Medical Products Administration (NMPA) granting marketing approval for its in-house developed human MTHFR gene polymorphism nucleic acid detection kit, which utilizes the PCR fluorescent probe method. This product is…
-
Sansure Biotech’s Tuberculosis Detection Kit Gains CE IVDR Certification for EU Market
•
Sansure Biotech Inc. (SHA: 688289), a leading molecular diagnostics company based in China, has announced that it has received CE IVDR certification from the European Union for its mycobacterium tuberculosis nucleic acid detection kit, which utilizes the PCR fluorescence probe method. This certification marks a significant milestone, as it grants…
-
Sansure Biotech Secures CE IVDR Certifications for Chemiluminescence Analyzers in the EU
•
China-based molecular diagnostics specialist, Sansure Biotech Inc., (SHA: 688289), has announced that it has received CE IVDR certifications in the European Union for two of its fully automatic chemiluminescence immunoassay analyzer products. This regulatory milestone marks a significant step forward for the company in expanding its presence in the EU…
-
Sansure Biotech Partners with Shaanxi Lifegen to Boost Molecular Diagnostics
•
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has formed a strategic partnership with fellow Chinese firm Shaanxi Lifegen Co. Ltd. The collaboration aims to deepen efforts in platform construction, sequencing, and full product development, although financial details of the partnership were not disclosed. Scope of the PartnershipThe partnership…
-
Sansure Biotech Secures CE Mark for 60 Molecular Diagnostic Products, Including Procalcitonin Assay Kit
•
Sansure Biotech Inc., a leading molecular diagnostics specialist based in China (SHA: 688289), has announced that it has received CE marks for 60 of its products, including a procalcitonin assay kit that utilizes chemiluminescent immunoassay technology. This significant milestone underscores the company’s commitment to expanding its global footprint and enhancing…
-
Sansure Biotech Partners with Indonesian Firm for Localized Molecular Diagnostic Production
•
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced a strategic partnership with an undisclosed firm from Indonesia. The collaboration will focus on the localized production of molecular diagnostic reagents and equipment, as well as other in vitro diagnostic (IVD) products. The partnership aims to train local molecular…
-
Sansure Biotech Partners with Shanghai Tenth People’s Hospital for Genomics Center
•
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has struck a partnership with Shanghai Tenth People’s Hospital to establish a precision genomics testing center. This collaboration aims to enhance the capabilities of both institutions in the field of genomics and molecular diagnostics. Precision Genomics Testing CenterSpecifically, the two parties…
-
Sansure Biotech Partners with Hunan Normal University for Research and Talent Development
•
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced a strategic partnership with Hunan Normal University. The collaboration aims to leverage the respective strengths of both entities to delve deeper into talent cultivation, scientific research, and platform co-construction, among other areas. No financial details of the partnership were…
-
Sansure Biotech’s Pertussis Detection Kit Approved by NMPA
•
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) announced that it has obtained medical device approval from the National Medical Products Administration (NMPA) for its pertussis nucleic acid detection kit (PCR fluorescence probe method). Product and ApplicationThe product, used for the auxiliary diagnosis of patients with respiratory tract infection…
-
Sansure Biotech Partners with UBC to Manufacture in Indonesia
•
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has entered into a local manufacturing memorandum of understanding (MoU) with its Indonesia partner UBC. The agreement will enable Sansure’s molecular diagnostics technology to be manufactured in Indonesia, aimed at enhancing infectious disease prevention and control, as well as diagnosis and…
